DOCSLIB.ORG

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution 1521-0081/72/2/486–526$35.00 https://doi.org/10.1124/pr.119.018440 PHARMACOLOGICAL REVIEWS Pharmacol Rev 72:486–526, April 2020 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: RICHARD D. YE Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution Uddalak Bharadwaj,1 Moses M. Kasembeli,1 Prema Robinson, and David J. Tweardy Department of Infectious Diseases, Infection Control & Employee Health, Division of Internal Medicine (U.B., M.M.K., P.R., D.J.T.), and Department of Molecular and Cellular Oncology (D.J.T.), University of Texas, MD Anderson Cancer Center, Houston, Texas Abstract. ....................................................................................488 Significance Statement ......................................................................488 I. Molecular and Cellular Biology of Janus Kinase/Signal Transducer and Activator of Downloaded from Transcription 3 Signaling. ..................................................................488 A. Canonical Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling . 488 1. Janus Kinases .......................................................................488 2. Signal Transducer and Activator of Transcription Proteins . .........................489 3. Negative Regulation of Canonical Janus Kinase/Signal Transducer and Activator of at MD Anderson Hosp Res Med Lib 99 on March 26, 2020 Transcription 3 Signaling. ............................................................490 4. Post-Translational Modifications of Signal Transducer and Activator of Transcrip- tion 3 . ..............................................................................490 a. Serine 727 phosphorylation . ......................................................490 b. Methylation.......................................................................491 c. Acetylation .......................................................................492 d. Ubiquitination, ISGylation, and SUMOylation .....................................492 B. Noncanonical Signal Transducer and Activator of Transcription 3 Activities . .............492 1. Phosphotyrosine 705–Unphosphorylated Signal Transducer and Activator of Transcription 3.......................................................................492 2. Mitochondrial Signal Transducer and Activator of Transcription 3. ...................493 3. Scaffold Function in Platelets. ......................................................493 4. Signal Transducer and Activator of Transcription 3 in the Endoplasmic Reticulum . 493 II. Biologic Functions of Janus Kinase/Signal Transducer and Activator of Transcription 3 in Basal Conditions ............................................................................494 A. Janus Kinase/Signal Transducer and Activator of Transcription 3 in Hematopoiesis and Immune Cell Function . ............................................................495 1. Granulopoiesis .......................................................................495 2. Platelets .............................................................................495 3. Dendritic Cells .......................................................................498 4. Phagocyte Function ..................................................................499 5. Natural Killer Cell Function..........................................................499 6. B Cells. ..............................................................................499 7. CD41 T Cells ........................................................................499 8. CD81 T Cells ........................................................................500 Address correspondence to: Dr. David J. Tweardy, Department of Infectious Diseases, Infection Control & Employee Health and Department of Molecular Cellular Oncology, University of Texas, MD Anderson Cancer Center, 1400 Pressler Street FCT12.5069, Unit 1463, Houston, TX 77030-3772. E-mail: [email protected] This work was supported by University of Texas for MD Anderson. Baylor College and Medicine, with D.J.T. as inventor, has filed 19 patents covering the use of TTI-101, a small-molecule inhibitor of STAT3 cited in this review. These patents are exclusively licensed to Tvardi Therapeutics, which was founded and is co-owned by D.J.T. 1U.B. and M.M.K. contributed equally to this work. doi.org/10.1124/pr.119.018440. 486 Targeting JAK/STAT3 Signaling 487 9. Anaphylaxis. ........................................................................500 B. Janus Kinase/Signal Transducer and Activator of Transcription 3 and Metabolism . .......500 1. Lipid Metabolism . ..................................................................500 2. Glucose Metabolism ..................................................................501 III. Functions of Janus Kinase/Signal Transducer and Activator of Transcription 3 in Stress Conditions ..................................................................................501 A. Radiation . ..............................................................................501 B. Oxidative Stress. ........................................................................502 C. Genotoxic Stress. ........................................................................503 D. Cell Senescence . ........................................................................503 E. Autophagy ..............................................................................503 F. Ischemia and Reperfusion Stress. ......................................................504 G. Hyperosmotic Stress . ..................................................................504 IV. Targeting Aberrant Janus Kinase/Signal Transducer and Activator of Transcription 3 Activity in Inflammatory, Fibrotic, Metabolic, and Oncological Diseases . ...................505 A. Strategies to Target Janus Kinases ......................................................505 B. Strategies to Target Signal Transducer and Activator of Transcription 3 ..................505 C. Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling and Its Targeting in Asthma . ..................................................................506 D. Janus Kinase/Signal Transducer and Activator of Transcription Signaling and Its Targeting in Anaphylaxis ................................................................506 E. Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling and Its Targeting in Inflammatory Bowel Disease................................................507 F. Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling and Its Targeting in Cachexia . ..................................................................507 G. Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling and Its Targeting in Fibrosis . ..................................................................508 H. Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling and Its Targeting in Metabolic Disorders . ......................................................509 I. Cancer ..................................................................................511 1. Janus Kinases in Cancer . ............................................................511 2. Targeting Janus Kinases in Cancer . ................................................511 3. Signal Transducer and Activator of Transcription 3 in Cancer .........................512 4. Targeting Signal Transducer and Activator of Transcription 3 in Cancer. .............512 a. Antisense oligonucleotide . ......................................................512 b. Signal transducer and activator of transcription 3 decoy oligonucleotides ...........512 c. Small-molecule inhibitors . ......................................................512 i. OPB-31121 . ..................................................................512 ii. OPB-111077..................................................................513 ABBREVIATIONS: AD-HIES, autosomal-dominant hyper-IgE syndrome; AE, adverse event; AgRP, agouti-related protein; Akt, Ak strain transforming; ALD, alcoholic liver disease; C/EBP, CCAAT/enhancer-binding protein; CD, Crohn’s disease; CK2, casein kinase 2; CLL, chronic lymphocytic leukemia; CNS, central nervous system; CRC, colorectal cancer; CSE, cigarette smoke extract; DC, dendritic cell; ECM, extra- cellular matrix; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; ET, essential thrombocythemia; ETC, electron transport chain; FERM, band four-point-one, ezrin, radixin, moesin; GAS, IFN-g activation site; GI, gastrointestinal; GVHD, graft-versus-host disease; HBEC, human bronchial epithelial cell; HCC, hepatocellular carcinoma; HDAC, methyltransferase histone deacetylase; HDM, house dust mite; HNSCC, head and neck squamous cell carcinoma; IBD, inflammatory bowel disease; IFN, interferon; IL, interleukin; iNOS, inducible NO synthase; IP3R3, inositol 1,4,5-trisphosphate receptor, type 3; I/R, ischemia–reperfusion; IR, ionizing radiation; IRS, insulin receptor substrate; ISG, IFN-stimulated gene; JAK, Janus kinase; Jakinib, JAK inhibitor; JH, JAK homology; JNK, c-Jun N-terminal kinase; Keap1, kelch-like ECH-associated protein 1; KO, knockout; MAPK, mitogen-activated protein kinase; MI, myocardial infarction; MMP, matrix metalloproteinase; MPN, myeloproliferative
Load more

Recommended publications
  • CVMP Assessment Report for APOQUEL (EMEA/V/C/002688/0000) International Non-Proprietary Name: Oclacitinib Maleate
    18 July 2013 EMA/481054/2013 Veterinary Medicines and Product Data Management Committee for Medicinal Products for Veterinary Use CVMP assessment report for APOQUEL (EMEA/V/C/002688/0000) International non-proprietary name: oclacitinib maleate Assessment report as adopted by the CVMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8447 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Introduction The applicant Pfizer Animal Health S.A. submitted on 26 July 2012 an application for marketing authorisation to the European Medicines Agency (The Agency) for APOQUEL, through the centralised procedure falling within Article 3(2)(a) of Regulation (EC) No 726/2004 (new active substance). During the procedure the applicant changed to Zoetis Belgium S.A. The eligibility to the centralised procedure was confirmed by the CVMP on 12 January 2012 falling under Article 3(2)(a) of Regulation (EC) No 726/2004 as APOQUEL contains a new active substance which was not authorised in the Community on the date of entry into force of the Regulation. APOQUEL film-coated tablets contain oclacitinib (as oclacitinib maleate) as the active substance. There are three different strengths of the (film-coated) tablets, containing 3.6 mg, 5.4 mg and 16 mg oclacitinib (as the maleate salt), and each is contained in blister packs (polychlorotrifluoroethylene (PCTFE)/polyvinylchloride (PVC)/aluminium) which are supplied in outer cartons containing 20 or 100 tablets.
    [Show full text]
  • Russia's Posture in Space
    Russia’s Posture in Space: Prospects for Europe Executive Summary Prepared by the European Space Policy Institute Marco ALIBERTI Ksenia LISITSYNA May 2018 Table of Contents Background and Research Objectives ........................................................................................ 1 Domestic Developments in Russia’s Space Programme ............................................................ 2 Russia’s International Space Posture ......................................................................................... 4 Prospects for Europe .................................................................................................................. 5 Background and Research Objectives For the 50th anniversary of the launch of Sputnik-1, in 2007, the rebirth of Russian space activities appeared well on its way. After the decade-long crisis of the 1990s, the country’s political leadership guided by President Putin gave new impetus to the development of national space activities and put the sector back among the top priorities of Moscow’s domestic and foreign policy agenda. Supported by the progressive recovery of Russia’s economy, renewed political stability, and an improving external environment, Russia re-asserted strong ambitions and the resolve to regain its original position on the international scene. Towards this, several major space programmes were adopted, including the Federal Space Programme 2006-2015, the Federal Target Programme on the development of Russian cosmodromes, and the Federal Target Programme on the redeployment of GLONASS. This renewed commitment to the development of space activities was duly reflected in a sharp increase in the country’s launch rate and space budget throughout the decade. Thanks to the funds made available by flourishing energy exports, Russia’s space expenditure continued to grow even in the midst of the global financial crisis. Besides new programmes and increased funding, the spectrum of activities was also widened to encompass a new focus on space applications and commercial products.
    [Show full text]
  • The Orbits of Saturn's Small Satellites Derived From
    The Astronomical Journal, 132:692–710, 2006 August A # 2006. The American Astronomical Society. All rights reserved. Printed in U.S.A. THE ORBITS OF SATURN’S SMALL SATELLITES DERIVED FROM COMBINED HISTORIC AND CASSINI IMAGING OBSERVATIONS J. N. Spitale CICLOPS, Space Science Institute, 4750 Walnut Street, Suite 205, Boulder, CO 80301; [email protected] R. A. Jacobson Jet Propulsion Laboratory, California Institute of Technology, 4800 Oak Grove Drive, Pasadena, CA 91109-8099 C. C. Porco CICLOPS, Space Science Institute, 4750 Walnut Street, Suite 205, Boulder, CO 80301 and W. M. Owen, Jr. Jet Propulsion Laboratory, California Institute of Technology, 4800 Oak Grove Drive, Pasadena, CA 91109-8099 Received 2006 February 28; accepted 2006 April 12 ABSTRACT We report on the orbits of the small, inner Saturnian satellites, either recovered or newly discovered in recent Cassini imaging observations. The orbits presented here reflect improvements over our previously published values in that the time base of Cassini observations has been extended, and numerical orbital integrations have been performed in those cases in which simple precessing elliptical, inclined orbit solutions were found to be inadequate. Using combined Cassini and Voyager observations, we obtain an eccentricity for Pan 7 times smaller than previously reported because of the predominance of higher quality Cassini data in the fit. The orbit of the small satellite (S/2005 S1 [Daphnis]) discovered by Cassini in the Keeler gap in the outer A ring appears to be circular and coplanar; no external perturbations are appar- ent. Refined orbits of Atlas, Prometheus, Pandora, Janus, and Epimetheus are based on Cassini , Voyager, Hubble Space Telescope, and Earth-based data and a numerical integration perturbed by all the massive satellites and each other.
    [Show full text]
  • Two CD95 Tumor Classes with Different Sensitivities to Antitumor Drugs
    Two CD95 tumor classes with different sensitivities to antitumor drugs Alicia Algeciras-Schimnich*†‡, Eric M. Pietras*‡, Bryan C. Barnhart*, Patrick Legembre*, Shrijay Vijayan*, Susan L. Holbeck§, and Marcus E. Peter*¶ *The Ben May Institute for Cancer Research, University of Chicago, 924 East 57th Street, Chicago, IL 60637; and §Developmental Therapeutics Program, Information Technology Branch, National Cancer Institute, 6130 Executive Boulevard, Room 8014, Bethesda, MD 20892-7444 Communicated by Stanley J. Korsmeyer, Dana–Farber Cancer Institute, Boston, MA, August 6, 2003 (received for review April 11, 2003) CD95 type I and II cells differ in their dependence on mitochondria mCD95L. Here we uncover a striking difference in the response to execute apoptosis, because antiapoptotic members of the Bcl-2 of type I and II tumor cell lines to different forms of CD95L. We family render only type II cells resistant to death receptor-induced found that a preparation of soluble sCD95L (S2) (9) efficiently apoptosis. They can also be distinguished by a more efficient kills type II cells. In contrast, type I cells are resistant to this formation of the death-inducing signaling complex in type I cells. cytotoxic activity. S2 therefore represents a tool for identifying We have identified a soluble form of CD95 ligand (S2) that is type I and II cells. We applied this tool to a collection of 58 tumor cytotoxic to type II cells but does not kill type I cells. By testing 58 cell lines of various histologic origin [of the Developmental tumor cell lines of the National Cancer Institute’s anticancer drug- Therapeutics Program of the National Cancer Institute (NCI)] screening panel for apoptosis sensitivity to S2 and performing (10).
    [Show full text]
  • 5.10.20 Final Part 1 No Prelimeary Pages
    IDENTIFICATION OF NOVEL TREATMENT APPROACHES FOR HUMAN AND CANINE OSTEOSARCOMA By Ya-Ting Yang A DISSERTATION Submitted to Michigan State University in partial fulfillment of the requirements for the degree of Comparative Medicine and Integrative Biology- Doctor of Philosophy 2020 ABSTRACT IDENTIFICATION OF NOVEL TREATMENT APPROACHES FOR HUMAN AND CANINE OSTEOSARCOMA By Ya-Ting Yang Osteosarcoma (OSA) is an aggressive neoplasm, characterized with high level of heterogeneity, high metastatic potential and poor prognosis in both humans and dogs. In this study, I used drug screening studies including existing therapeutic agents and novel compounds to identify more effective approaches to treat human and canine osteosarcoma. One of the challenges in the field of OSA is to identify optimal tools for study. A limited number of human and canine OSA cell lines are available. In this study, I established and characterized a new cell line, BZ, derived from a German shepherd dog with OSA and studied key oncogenic pathways in BZ. Our findings revealed activation of STAT3 and ERK pathways in BZ, as well as in a number of other cell lines, indicating that these two pathways are critical for cell survival and proliferation in OSA and the potential of using STAT3 and ERK inhibitors. Furthermore, I screened ten tyrosine kinase inhibitors (TKIs) on two dog and one human OSA cell lines. Among the selected TKIs, sorafenib showed promising results in effectively inhibited cell growth and migration in vitro studies. In addition, the effects of combing sorafenib with current chemotherapeutics (cisplatin, carboplatin, and doxorubicin) for OSA were investigated. Data from the combination index pointed to synergistic effects of sorafenib combined with doxorubicin and resulted in profound cell arrest at G2/M phase.
    [Show full text]
  • Single Cell RNA-Seq and Mass Cytometry Reveals a Novel and a Targetable Population Of
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.04.425268; this version posted January 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Single Cell RNA-seq and Mass Cytometry Reveals a Novel and a Targetable Population of Macrophages in Idiopathic Pulmonary Fibrosis Authors: 5 Ayaub EA4*, Poli S2*, Ng J4, Adams T3, Schupp J3, Quesada-Arias L2, Poli F1, Cosme C3, Robertson M6 , Martinez-Manzano J4, Liang X1,4, Villalba J5, Lederer J4, Chu SG4, Raby BA4, Washko G4, Coarfa C6, Perrella MA4, El-Chemaly S4, Kaminski N3, Rosas IO1 Author Affiliations: 10 1 Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA 2 Mount Sinai Medical Center, Division of Internal Medicine, Miami Beach, FL, USA. 3 Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA 4Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 15 5 Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6 Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA 20 *These authors contributed equally to the work 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.04.425268; this version posted January 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Author Contributions: EA, SP, IOR, and NK conceptualized the study.
    [Show full text]
  • Leonid Gurvits JIVE and TU Delft June 3, 2021 ©Cristian Fattinanzi Piter Y Moons Xplorer
    Leonid Gurvits JIVE and TU Delft June 3, 2021 ©Cristian Fattinanzi piter y moons xplorer Why a mission to Jupiter? Bits of history Mission challenges Where radio astronomy comes in • ~2000–2005: success of Cassini and Huygens missions (NASA, ESA, ASI) • 2006: Europlanet meeting in Berlin – “thinking aloud” on a Jovian mission • 2008: ESA-NASA jointly exploring a mission to giant planets’ satellites • ESA "Laplace" mission proposal (Blanc et al. 2009) • ESA Titan and Enceladus Mission (TandEM, Coustenis et al., 2009) • NASA Titan Explorer • 2009: two joint (ESA+NASA) concepts selected for further studies: • Europa Jupiter System Mission (EJSM) • Titan Saturn System Mission (TSSM: Coustenis et al., 2009) • 2010: EJSM-Laplace selected, consisting of two spacecraft: • ESA’s Jupiter Ganymede Orbiter (JGO) • NASA’s Jupiter Europa Orbiter (JEO) • 2012: NASA drops off; EJSM-Laplace/JGO becomes JUICE • 2013: JUICE payload selection completed by ESA; JUICE becomes an L-class mission of ESA’s Vision 2015-2025 • 2015: NASA selects Europa Clipper mission (Pappalardo et al., 2013) Voyager 1, 1979 ©NASA HOW DOES IT SEARCH FOR ORIGINS & WORK? LIFE FORMATION HABITABILITY Introduction Overarching questions JUICE JUICE Science Themes • Emergence of habitable worlds around gas giants • Jupiter system as an archetype for gas giants JUICE concept • European-led mission to the Jovian system • First orbiter of an icy moon • JGO/Laplace scenario with two Europa flybys and moderate-inclination phase at Jupiter • Science payload selected in Feb 2013, fully compatible
    [Show full text]
  • Cucurbitacin Q: a Selective STAT3 Activation Inhibitor with Potent Antitumor Activity
    Oncogene (2005) 24, 3236–3245 & 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00 www.nature.com/onc Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity Jiazhi Sun1,2, Michelle A Blaskovich1,2, Richard Jove1, Sandra K Livingston1, Domenico Coppola1 and Saı¨ d M Sebti*,1 1Departments of Interdisciplinary Oncology and Biochemistry and Molecular Biology, Drug Discovery and Molecular Oncology Programs, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, MRC-DRDIS, Tampa, FL 33612-9497, USA Constitutive activation of the JAK/STAT3 pathway is a Introduction major contributor to oncogenesis.In the present study, structure–activity relationship (SAR) studies with five Signal transducers and activators of transcription cucurbitacin (Cuc) analogs, A, B, E, I, and Q, led to the (STATs) are a family of seven proteins (STATs 1, 2, 3, discovery of Cuc Q, which inhibits the activation of 4, 5a, 5b, and 6) unique in their ability both to transduce STAT3 but not JAK2; Cuc A which inhibits JAK2 but not extracellular signals and regulate transcription directly. STAT3 activation; and Cuc B, E, and I, which inhibit the STATs transduce extracellular signals from cytokines activation of both.Furthermore, these SAR studies such as interleukin-6 and interferons or growth factors demonstrated that conversion of the C3 carbonyl of the such as platelet-derived growth factor (PDGF) and cucurbitacins to a hydroxyl results in loss of anti-JAK2 epidermal growth factor (EGF). Upon activation of activity, whereas addition of a hydroxyl group to C11 of these receptors, STATs are recruited to the plasma the cucurbitacins results in loss of anti-STAT3 activity.
    [Show full text]
  • The Role of Stat5 Transcription Factors As Tumor Suppressors Or Oncogenes
    Biochimica et Biophysica Acta 1815 (2011) 104–114 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbacan Review The role of Stat5 transcription factors as tumor suppressors or oncogenes G. Ferbeyre a,⁎, R. Moriggl b,⁎ a Département de Biochimie, Université de Montréal, Montréal, Québec H3C 3J7, Canada b Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria article info abstract Article history: Stat5 is constitutively activated in many human cancers affecting the expression of cell proliferation and cell Received 9 September 2010 survival controlling genes. These oncogenic functions of Stat5 have been elegantly reproduced in mouse Received in revised form 8 October 2010 models. Aberrant Stat5 activity induces also mitochondrial dysfunction and reactive oxygen species leading to Accepted 8 October 2010 DNA damage. Although DNA damage can stimulate tumorigenesis, it can also prevent it. Stat5 can inhibit Available online 20 October 2010 tumor progression like in the liver and it is a tumor suppressor in fibroblasts. Stat5 proteins are able to regulate cell differentiation and senescence activating the tumor suppressors SOCS1, p53 and PML. Keywords: Stat5 Understanding the context dependent regulation of tumorigenesis through Stat5 function will be central to Jak–Stat signaling understand proliferation, survival, differentiation or senescence of cancer cells. Senescence © 2010 Elsevier B.V. All rights reserved. Mouse models Contents 1. Introduction .............................................................. 105 2. Activation of Stat5 proteins and insights from different cancers ...................................... 105 2.1. The role of Stat5 protein activation in hematopoietic neoplasms .................................. 105 2.2. Activation or inactivation of Stat5 proteins by viruses: HTLV-I and HIV ............................... 106 2.3.
    [Show full text]
  • Successful Treatment of Atopic Dermatitis with the JAK1 Inhibitor Oclacitinib
    PROC (BAYL UNIV MED CENT) 2018;31(4):524–525 Copyright # 2018 Baylor University Medical Center https://doi.org/10.1080/08998280.2018.1480246 Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib Isabel M. Haugh, MB, BAO, BCha, Ian T. Watson,b and M. Alan Menter, MDa aDepartment of Dermatology, Baylor University Medical Center, Dallas, Texas; bTexas A&M College of Medicine, Bryan, Texas ABSTRACT We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treat- ment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans. KEYWORDS Atopic dermatitis; eczema; JAK1; oclacitinib clacitinib is a Janus kinase-1 (JAK1) inhibitor DISCUSSION approved for the treatment of pruritus secondary Oclacitinib selectively inhibits JAK1 of the JAK signal O to allergic dermatitis and atopic dermatitis in transducer and activator of transcription (JAK-STAT) path- canines. JAK1 plays a role in the expression of way, which plays a central role in cytokine signaling of pro- interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 inflammatory cytokines in atopic dermatitis, both in dogs (IL-13) in proinflammatory signaling pathways known to and in humans.
    [Show full text]
  • Safety and Toxicity of Combined Oclacitinib and Carboplatin Or Doxorubicin in Dogs with Solid Tumors: a Pilot Study Laura E
    Barrett et al. BMC Veterinary Research (2019) 15:291 https://doi.org/10.1186/s12917-019-2032-4 RESEARCH ARTICLE Open Access Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study Laura E. Barrett1, Heather L. Gardner2, Lisa G. Barber1, Abbey Sadowski1 and Cheryl A. London1* Abstract Background: Oclacitinib is an orally bioavailable Janus Kinase (JAK) inhibitor approved for the treatment of canine atopic dermatitis. Aberrant JAK/ Signal Transducer and Activator of Transcription (STAT) signaling within hematologic and solid tumors has been implicated as a driver of tumor growth through effects on the local microenvironment, enhancing angiogenesis, immune suppression, among others. A combination of JAK/STAT inhibition with cytotoxic chemotherapy may therefore result in synergistic anti-cancer activity, however there is concern for enhanced toxicities. The purpose of this study was to evaluate the safety profile of oclacitinib given in combination with either carboplatin or doxorubicin in tumor-bearing dogs. Result: Oclacitinib was administered at the label dose of 0.4–0.6 mg/kg PO q12h in combination with either carboplatin at 250-300 mg/m2 or doxorubicin at 30 mg/m2 IV q21d. Nine dogs were enrolled in this pilot study (n =4 carboplatin; n = 5 doxorubicin). No unexpected toxicities occurred, and the incidence of adverse events with combination therapy was not increased beyond that expected in dogs treated with single agent chemotherapy. Serious adverse events included one Grade 4 thrombocytopenia and one Grade 4 neutropenia. No objective responses were noted. Conclusions: Oclacitinib is well tolerated when given in combination with carboplatin or doxorubicin.
    [Show full text]
  • HUMAN ADAPTATION to SPACEFLIGHT: the ROLE of FOOD and NUTRITION Second Edition
    National Aeronautics and Human Space Administration Adaptation to Spaceflight: The Role of Food and Nutrition Second Edition Scott M. Smith Sara R. Zwart Grace L. Douglas Martina Heer National Aeronautics and Space Administration HUMAN ADAPTATION TO SPACEFLIGHT: THE ROLE OF FOOD AND NUTRITION Second Edition Scott M. Smith Grace L. Douglas Nutritionist; Advanced Food Technology Lead Scientist; Manager for Nutritional Biochemistry Manager for Exploration Food Systems Nutritional Biochemistry Laboratory Space Food Systems Laboratory Biomedical Research and Human Systems Engineering and Environmental Sciences Division Integration Division Human Health and Performance Human Health and Performance Directorate Directorate NASA Johnson Space Center NASA Johnson Space Center Houston, Texas USA Houston, Texas USA Sara R. Zwart Martina Heer Senior Scientist; Nutritionist; Deputy Manager for Nutritional Program Director Nutritional Sciences Biochemistry IU International University of Nutritional Biochemistry Laboratory Applied Sciences Biomedical Research and Bad Reichenhall, Germany Environmental Sciences Division & Human Health and Performance Adjunct Professor of Nutrition Physiology Directorate Institute of Nutritional and Food Sciences NASA Johnson Space Center University of Bonn, Germany Houston, Texas USA & Preventive Medicine and Population Health University of Texas Medical Branch Galveston, Texas USA Table of Contents Preface .........................................................................................................................
    [Show full text]